Gonadotropin-releasing hormone agonist in premenopausal women does not alter hypothalamic-pituitary-adrenal axis response to corticotropin-releasing hormone

被引:6
|
作者
Gavin, Kathleen M. [1 ,2 ]
Shea, Karen L. [1 ,2 ]
Gibbons, Ellie [1 ]
Wolfe, Pamela [3 ]
Schwartz, Robert S. [1 ,2 ]
Wierman, Margaret E. [4 ]
Kohrt, Wendy M. [1 ,2 ]
机构
[1] Univ Colorado, Div Geriatr Med, Sch Med, Anschutz Med Campus, Aurora, CO USA
[2] Vet Affairs Eastern Colorado Heath Care Syst, Educ & Clin Ctr, Geriatr Res, Denver, CO USA
[3] Univ Colorado, Dept Preventat Med & Biostat, Anschutz Med Campus, Aurora, CO USA
[4] Univ Colorado, Div Endocrinol Metab & Diabet, Anschutz Med Campus, Aurora, CO USA
关键词
central adiposity; cortisol; estradiol; gonadotropin-releasing hormone agonist; menopause; BODY-FAT DISTRIBUTION; 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE-1; CORTISOL AWAKENING RESPONSE; LEUPRORELIN ACETATE DEPOT; POSTMENOPAUSAL WOMEN; MENSTRUAL-CYCLE; ESTRADIOL TREATMENT; ENERGY-EXPENDITURE; METABOLIC SYNDROME; BINDING GLOBULIN;
D O I
10.1152/ajpendo.00221.2017
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Sex honnones appear to play a role in the regulation of hypothalamic-pituitary-adrenal (HPA) axis activity. The objective was to isolate the effects of estradiol (E-2) on central activation of the HPA axis. We hypothesized that the HPA axis response to corticotropin-releasing hormone (CRH) under dexamethasone (Dex) suppression would be exaggerated in response to chronic ovarian hormone suppression and that physiologic E-2 add-back would mitigate this response. Thirty premenopausal women underwent 20 wk of gonadotropin-releasing hormone agonist therapy (GnRH(AG)) and transderma] E-2 (0.075 mg per day, GnRH(AG), + E-2, n = 15) or placebo (PL) patch (GnRH(AG) + PL, n = 15). Women in the GnRH(AG) + PL and GnRH(AG) + E-2 groups were of similar age (38 (SD 5) yr vs. 36 (SD 7) yr) and body mass index (27 (SD 6) kg/m(2) vs. 27 (SD 6) kg/m(2)). Serum E-2 changed differently between the groups (P = 0.01); it decreased in response to GnRH(AG) + PL (77.9 +/- 17.4 to 23.2 +/- 2.6 pg/ml; P = 0.008) and did not change in response to GnRH(AG) + E-2 (70.6 +/- 12.4 to 105 +/- 30.4 pg/ml; P = 0.36). The incremental area under the curve (AUC(INC)) responses to CRH were different between the groups for total cortisol (P = 0.03) and cortisone (P = 0.04) but not serum adrenocorticotropic hormone (ACTH) (P = 0.28). When examining within-group changes. GnRH(AG) + PL did not alter the HPA axis response to Dex/CRH, but GnRH(AG) + E-2 decreased the AUC(INC) for ACTH (AUC(INC), 1,623 +/- 257 to 1,211 +/- 236 pg/ml center dot min, P = 0.004). cortisone (1.795 +/- 367 to 1.090 +/- 281 ng/ml center dot min, P = 0.009), and total cortisol (7.008 +/- 1.387 to 3,893 +/- 1,090 ng/ml center dot min, P = 0.02). Suppression of ovarian hormones by GnRH(AG) therapy for 20 wk did not exaggerate the HPA axis response to CRH, but physiologic E-2 add-back reduced HPA axis activity compared with preintervention levels.
引用
收藏
页码:E316 / E325
页数:10
相关论文
共 50 条
  • [41] Gonadotropin-releasing hormone agonist-induced pituitary apoplexy
    Keane, Fergus
    Egan, Aoife M.
    Navin, Patrick
    Brett, Francesca
    Dennedy, Michael C.
    ENDOCRINOLOGY DIABETES AND METABOLISM CASE REPORTS, 2016,
  • [42] EFFECTS OF CORTICOTROPIN RELEASING HORMONE AND CORTICOTROPIN RELEASING HORMONE ANTAGONIST ON BIOSYNTHESIS OF GONADOTROPIN RELEASING HORMONE AND GONADOTROPIN RELEASING HORMONE RECEPTOR IN THE HYPOTHALAMIC-PITUITARY UNIT OF FOLLICULAR-PHASE EWES AND CONTRIBUTION OF KISSPEPTIN
    Ciechanowska, M.
    Kowalczyk, M.
    Lapot, M.
    Malewski, T.
    Antkowiak, B.
    Brytan, M.
    Winnicka, I
    Przekop, F.
    JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, 2018, 69 (03): : 451 - 461
  • [43] Redistribution of Gq/11α in the pituitary gonadotrope in response to a gonadotropin-releasing hormone agonist
    Cornea, A
    Janovick, JA
    Stanislaus, D
    Conn, PM
    ENDOCRINOLOGY, 1998, 139 (01) : 397 - 402
  • [44] Aging Attenuates the Pituitary Response to Gonadotropin-Releasing Hormone
    Shaw, Natalie D.
    Srouji, Serene S.
    Histed, Stephanie N.
    McCurnin, Kristin E.
    Hall, Janet E.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2009, 94 (09): : 3259 - 3264
  • [45] EFFECT OF CLOMIPHENE ON PITUITARY RESPONSE TO GONADOTROPIN-RELEASING HORMONE
    HOMBURG, R
    INSLER, V
    LUNENFELD, B
    POTASHNIK, G
    ESHKOL, A
    BIRENBOIM, N
    ISRAEL JOURNAL OF MEDICAL SCIENCES, 1975, 11 (05): : 518 - 518
  • [46] Development of Gonadotropin-Releasing Hormone Secretion and Pituitary Response
    Glanowska, Katarzyna M.
    Burger, Laura L.
    Moenter, Suzanne M.
    JOURNAL OF NEUROSCIENCE, 2014, 34 (45): : 15060 - 15069
  • [47] THE FREQUENCY OF GONADOTROPIN-RELEASING HORMONE STIMULATION DETERMINES THE NUMBER OF PITUITARY GONADOTROPIN-RELEASING HORMONE RECEPTORS
    KATT, JA
    DUNCAN, JA
    HERBON, L
    BARKAN, A
    MARSHALL, JC
    ENDOCRINOLOGY, 1985, 116 (05) : 2113 - 2115
  • [48] Differential regulation of gonadotropin-releasing hormone by corticotropin-releasing factor family peptides in hypothalamic N39 cells
    Kageyama, Kazunori
    Hasegawa, Gen
    Akimoto, Kanako
    Yamagata, Satoshi
    Tamasawa, Naoki
    Suda, Toshihiro
    PEPTIDES, 2012, 33 (01) : 149 - 155
  • [49] PITUITARY RESPONSE TO THYROTOPIN RELEASING HORMONE (TRH) AND GONADOTROPIN-RELEASING HORMONE (GNRH) IN PATIENTS WITH HYDROCEPHALUS
    HULUGALLE, RS
    GOLLAPUDI, GM
    ROSEN, A
    CLINICAL RESEARCH, 1978, 26 (03): : A307 - A307
  • [50] Hypoxia effects on hypothalamic corticotropin-releasing hormone and anterior pituitary cAMP
    Chen, Z
    Du, JZ
    ACTA PHARMACOLOGICA SINICA, 1996, 17 (06): : 489 - 492